Model-Informed Precision Dosing of Isoniazid: Parametric Population Pharmacokinetics Model Repository
Gehang Ju,Xin Liu,Wenyu Yang,Nuo Xu,Lulu Chen,Chenchen Zhang,Qingfeng He,Xiao Zhu,Dongsheng Ouyang
DOI: https://doi.org/10.2147/dddt.s434919
IF: 4.3188
2024-03-14
Drug Design Development and Therapy
Abstract:Gehang Ju, 1– 3 Xin Liu, 1– 3 Wenyu Yang, 4 Nuo Xu, 4 Lulu Chen, 3, 5 Chenchen Zhang, 6 Qingfeng He, 4 Xiao Zhu, 4, &ast Dongsheng Ouyang 1– 3, 5, &ast 1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, People's Republic of China; 2 Institute of Clinical Pharmacology, Central South University, Changsha, People's Republic of China; 3 Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd, Changsha, People's Republic of China; 4 Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, People's Republic of China; 5 Changsha Duxact Biotech Co., Ltd, Changsha, People's Republic of China; 6 School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Dongsheng Ouyang; Xiao Zhu, Email ; Introduction: Isoniazid (INH) is a crucial first-line anti tuberculosis (TB) drug used in adults and children. However, various factors can alter its pharmacokinetics (PK). This article aims to establish a population pharmacokinetic (popPK) models repository of INH to facilitate clinical use. Methods: A literature search was conducted until August 23, 2022, using PubMed, Embase, and Web of Science databases. We excluded published popPK studies that did not provide full model parameters or used a non-parametric method. Monte Carlo simulation works was based on RxODE. The popPK models repository was established using R. Non-compartment analysis was based on IQnca. Results: Fourteen studies included in the repository, with eleven studies conducted in adults, three studies in children, one in pregnant women. Two-compartment with allometric scaling models were commonly used as structural models. NAT2 acetylator phenotype significantly affecting the apparent clearance (CL). Moreover, postmenstrual age (PMA) influenced the CL in pediatric patients. Monte Carlo simulation results showed that the geometric mean ratio (95% Confidence Interval, CI) of PK parameters in most studies were within the acceptable range (50.00– 200.00%), pregnant patients showed a lower exposure. After a standard treatment strategy, there was a notable exposure reduction in the patients with the NAT2 RA or nonSA (IA/RA) phenotype, resulting in a 59.5% decrease in AUC 0-24 and 83.2% decrease in C max (Infants), and a 49.3% reduction in AUC 0-24 and 73.5% reduction in C max (Adults). Discussion: Body weight and NAT2 acetylator phenotype are the most significant factors affecting the exposure of INH. PMA is a crucial factor in the pediatric population. Clinicians should consider these factors when implementing model-informed precision dosing of INH. The popPK model repository for INH will aid in optimizing treatment and enhancing patient outcomes. Keywords: Isoniazid, model-informed precision dosing, population pharmacokinetics, nonlinear mixed-effects model Globally, tuberculosis is a highly contagious disease that causes significant morbidity and mortality. It was the leading cause of death from a single infectious agent before the coronavirus (COVID-19) pandemic, surpassing even HIV/AIDS. According to the World Health Organization (WHO) tuberculosis report of 2022, 6.4 million people were newly diagnosed with TB. Although there was an 86% success rate for treating drug-susceptible TB in 2021, 1 a significant proportion of patients showed inadequate treatment response, primarily due to insufficient anti-TB drug exposure. 2 In the field of TB management, isoniazid is considered the most crucial first-line drug for both adults and children. 3 The WHO recommends daily doses of 300mg (range, 4–5mg/kg) for patients aged 10 years and older, and 10mg/kg (range, 7–15mg/kg) for those under 10 years, while also advising using body weight as a covariate to customize anti-TB administration. 4 The treatment outcome for first-line TB drugs is mainly predicted by the area under the concentration-time curve over a dosing interval (AUC 0–24 ) relative to the minimal inhibitory concentration and peak concentration (C max ). 5–7 For isoniazid, the desired exposure is C max (3–6mg/L) and AUC 0-24 (52mg*h/L). 7–9 Isoniazid is primarily metabolized by hepatic N-acetyltransferase 2 (NAT2) and is the main candidate among TB drugs for genotype-based dose individualization. 10 NAT2 phenotypes, such as slow acetylators (SA), intermediate acetylator -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal